"Prednisone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
| Descriptor ID |
D011241
|
| MeSH Number(s) |
D04.210.500.745.432.719.702
|
| Concept/Terms |
Prednisone- Prednisone
- Dehydrocortisone
- delta-Cortisone
|
Below are MeSH descriptors whose meaning is more general than "Prednisone".
Below are MeSH descriptors whose meaning is more specific than "Prednisone".
This graph shows the total number of publications written about "Prednisone" by people in this website by year, and whether "Prednisone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 |
| 1996 | 1 | 4 | 5 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 5 | 6 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 5 | 6 |
| 2003 | 1 | 6 | 7 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 5 | 6 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 4 | 4 |
| 2013 | 1 | 6 | 7 |
| 2014 | 0 | 8 | 8 |
| 2015 | 2 | 6 | 8 |
| 2016 | 1 | 4 | 5 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 6 | 7 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prednisone" by people in Profiles.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL). J Geriatr Oncol. 2025 Jan; 16(1):102160.
-
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features. Arch Pathol Lab Med. 2024 Aug 01; 148(8):914-920.
-
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024 Sep; 11(9):e671-e681.
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP. Front Immunol. 2024; 15:1324113.
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023 11 28; 7(22):7141-7150.
-
Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. Leuk Lymphoma. 2023 12; 64(14):2258-2268.